Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of HS022 and Trastuzumab® in Combination With Vinorelbine Bitartrate Injection in the Treatment of HER2-positive Breast Cancer

NCT06107790 | Completed Phase 3

• 1 other identifier: HS022-III
• Study Type: interventional
• Target: 570
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-center, randomized, double-blind, parallel-group study to evaluate the efficacy and safety and Immunogenicity of Vinorelbine Bitartrate Injection in Combination With HS022 and Trastuzumab®.There were 2 parts. Part 1 needs 8 treatment cycles ( at least 24 weeks); Part2 needs 9 treatment cycles (at least 27 weeks).

Conditions

HER2-positive Breast Cancer

Outcome Measures

Primary Outcomes (1)

• ORR

  The best overall response rate (ORR24: performed at the 25th week): According to the Solid Tumor Efficacy Evaluation Standard (RECIST) 1.1, the proportion of CR and PR subjects from the first evaluation (baseline) to the 25th week of treatment (after the completion of 8 treatment cycles) (note: including unconfirmed response).

  WEEK 25

Secondary Outcomes (13)

• DCR

  WEEK 25

• PFS

  WEEK 52

• OS

  WEEK 52

• Vital signs

  first day and the 8th day at each visit prior to administration（1st cycle , the 2nd cycle, the 3rd cycle, the 4th cycle the 5th cycle, the 6th cycle,the 7th cycle,the 8th cycle,or the 22nd day after the last administration of the early withdrawal.

• Vital signs

  first day and the 8th day at each visit prior to administration（1st cycle , the 2nd cycle, the 3rd cycle, the 4th cycle the 5th cycle, the 6th cycle,the 7th cycle,the 8th cycle,or the 22nd day after the last administration of the early withdrawal.

Study Arms (2)

HS022+ Vinorelbine Bitartrate

EXPERIMENTAL

Drug: HS022; Drug: Vinorelbine Bitartrate

Trastuzumab®+ Vinorelbine Bitartrate Injection

ACTIVE COMPARATOR

Drug: Trastuzumab; Drug: Vinorelbine Bitartrate

Interventions

HS022 DRUG

8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first. The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg

HS022+ Vinorelbine Bitartrate

Trastuzumab DRUG

8 treatment cycles, 3 weeks/cycle, 24 weeks. The first dose is 8 mg/kg , and then 6 mg/kg .3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first. The second stage 9 treatment cycles, 3 weeks/cycle, 27 weeks. 6mg/kg

Trastuzumab®+ Vinorelbine Bitartrate Injection

Vinorelbine Bitartrate DRUG

Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first. Second section:9 treatment cycles, 3 weeks/cycle, 27 weeks. Vinorelbine: 25mg/m2 (intravenous infusion, day 1 and 8 of each cycle). The investigator may decide whether to continue treatment with vinorelbine at his discretion. 3 weeks/cycle, continue until the disease progresses, intolerable toxic reaction occurs, or the subject voluntarily withdraws from the clinical trial, whichever occurs first.

HS022+ Vinorelbine Bitartrate; Trastuzumab®+ Vinorelbine Bitartrate Injection

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Female ≥18 and ≤75 years of age on day of signing the informed consent form (ICF).
• \. Histologically or cytologically confirmed adenocarcinoma of the breast. 3. Recurrent disease not amenable to curative surgery or radiation therapy. 4. HER2-positivity, based on IHC score 3+ or ISH positivity. For those IHC score 2+ patients, fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH) or silver enhanced in situ hybridization (SISH) should be tested to prove HER2 gene amplification.
• No prior systemic anticancer agent such as chemotherapy, biological or targeted agent for metastatic disease. For patients with recurrent disease, prior neo-/adjuvant therapy containing trastuzumab must have been stopped at least 12 months before the diagnosis of recurrent (local or metastatic) disease.
• Those with at least one measurable target lesion (RECIST 1.1 standard): at least one diameter line of the target lesion can be accurately measured, and the lesions, skin lesions, brain lesions, and bone metastases of any type after radiotherapy or other local regional treatment can only be evaluated as non-target lesions; 7.ECOG \< 2； 8.Left ventricular ejection fraction (LVEF) ≥ 50% within 4 weeks before randomization; 9.Adequate hematology, liver function and kidney function, as shown in the following laboratory test values；
• a) Absolute value of neutrophil ≥ 1.5 × 109/L； b) Platelet ≥ 100 × 109/L, and hemoglobin ≥ 90g/L; c) Total serum bilirubin ≤ 1.5 times the upper limit of normal value (except for Gilbert syndrome); d) ALT and AST ≤ 2.5 times the upper limit of normal value (subjects with liver metastasis ≤ 5 times the upper limit of normal value); e) Blood creatinine ≤ 1.5 times the upper limit of normal value. 10.The expected survival period ≥ 3 months. 11. Patients have voluntarily agreed to participate and given written informed consent.

You may not qualify if:

• Prior surgery within 4 weeks preceeding enrollment or expected to be performed during the trial, prior chemotherapy wihtin 4 weeks preceeding enrollment, prior radiotherapy or endocrinotherapy within 4 weeks before enrollment.
• Participation in another clinical study within 4 weeks before enrollment (3 months for studies involving monoclonal therapy), excluding those who failed in screening;
• \. Patients with any other malignant tumor in the past five years, excluding fully cured cervical carcinoma in situ, basal cell or squamous cell skin cancer;
• \. Have a clear history of neurological or mental disorders, including epilepsy or dementia;
• \. Those who are allergic to any ingredient or excipient of the test drug, including those who are allergic to benzyl alcohol;
• \. Those who have received whole blood or component blood transfusion within 2 weeks before randomization;
• \. Those who currently suffer from diseases affecting intravenous injection and venous blood collection;
• \. At present, there are serious and uncontrollable systemic diseases (such as dyspnea, bronchospasm, acute attack of asthma or other diseases requiring continuous oxygen inhalation treatment), which, according to the judgment of the researcher, will significantly affect the participation/completion of the test and efficacy evaluation of the subjects;
• \. Have any of the following heart diseases:
• Currently suffering from untreated or uncontrollable hypertension (systolic blood pressure\>150 mmHg or diastolic blood pressure\>100 mmHg), or unstable angina pectoris;
• According to the standards of the New York Heart Association, he currently has a history of congestive heart failure at any level, or serious arrhythmia requiring treatment (excluding atrial fibrillation or paroxysmal supraventricular tachycardia);
• Myocardial infarction occurred within 6 months before signing the informed consent;
• \. At present, people who need to use corticosteroids daily for long-term treatment (the equivalent dose of methylprednisolone with dose\>10 mg/day), excluding inhaled corticosteroids; 14. Any one of human immunodeficiency virus antibody, treponema pallidum antibody and hepatitis C virus antibody should be excluded. Or there are patients with active hepatitis B infection of clinical significance who need treatment: hepatitis B surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\] is positive, and hepatitis B virus deoxyribonucleic acid \[HBV DNA\] test results are greater than or equal to the upper limit of the reference value of each hospital. Among them, only those with positive syphilis specific antibody test but negative syphilis non-specific antibody test can be selected; Only those with positive hepatitis C virus antibody but negative hepatitis C virus RNA \[HCV RNA\] can be selected;;
• \. Pregnant or lactating women; Or when screening, the blood pregnancy test of women of childbearing age is positive; Or women of childbearing age and their spouses are unwilling to take effective contraceptive measures during and within 7 months after the end of the clinical trial;
• The researcher believes that it is not suitable for enrollment or may not be able to complete the test for other reasons.

Sponsors & Collaborators

• Zhejiang Hisun Pharmaceutical Co. Ltd.: lead

Study Sites (1)

Jiangsu Province People's Hospital (First Affiliated Hospital of Nanjing Medical University)

Nanjing, Jiangsu, 210029, China

Location

MeSH Terms

Interventions

Trastuzumab

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 16, 2023
• First Posted: October 30, 2023
• Study Start: May 16, 2018
• Primary Completion: January 28, 2022
• Study Completion: January 28, 2022
• Last Updated: October 30, 2023

Record last verified: 2023-09

Locations

CN (1)